Stay updated on Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page
- ChecktodayChange DetectedRevision: v3.4.1 was added and v3.4.0 removed; this appears to be a version-label update with no substantive changes to the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoChange DetectedAdded Assuntina Sacco, MD as a study contact and removed Ezra Cohen, MD; updated QC status to 'Last Update Submitted that Met QC Criteria' with revision to v3.4.0. Introduced a new Show glossary option and updated metadata entries including 2026-01-28, 2026-01-26, and No FEAR Act Data.SummaryDifference0.5%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA minor revision update is shown: Revision: v3.3.4 has been added (replacing v3.3.3), and it does not affect substantive content on the study page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded a dedicated Locations section with California as a listed study site, clarifying where the trial is conducted. Removed the older California Locations label and the HHS Vulnerability Disclosure link as part of the prior revision.SummaryDifference0.2%

- Check65 days agoChange DetectedThe terms 'Head and neck squamous cell carcinoma' and the related topic 'MedlinePlus Genetics' have been removed from the page.SummaryDifference0.2%

- Check72 days agoChange DetectedRelated topics were added (Head and neck squamous cell carcinoma; MedlinePlus Genetics) and the page revision label updated from v3.2.0 to v3.3.2. These are metadata updates and do not affect the study details.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Head and Neck Cancer Clinical Trial page.